Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Central Nervous System Neoplasms × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Cholangiocarcinoma 4 Urinary Bladder Neoplasms 3 Acrocephalosyndactylia 3 Stomach Neoplasms 2 Glioblastoma 2 Uterine Cervical Neoplasms 1 Upper Tract Urothelial Carcinomas 1 Tumor With Alterations of the FGF-R 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Rectal Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1 Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Radiotherapy 105 Temozolomide 96 Carboplatin 45 Filgrastim 39 Vincristine 36 Etoposide 34 Cyclophosphamide 32 Chemotherapy, Adjuvant 31 Carmustine 29 Cisplatin 28 Irinotecan 23 Peripheral Blood Stem Cell Transplantation 22 Magnetic Resonance Spectroscopy 22 Lomustine 21 Thiotepa 19 Procarbazine 16 Methotrexate 16 Granulocyte Colony-Stimulating Factor 16 Bevacizumab 16 Surgical Procedures, Operative 13 etoposide phosphate 11 Thalidomide 11 O(6)-benzylguanine 11 sargramostim 10 Radiation 10 Drug Therapy 10 Topotecan 9 Ifosfamide 9 Busulfan 9 Paclitaxel 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05222165 2023-02-23

NEWEL

Helsinn Healthcare SA

Phase 1/2 Withdrawn

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡